Early Systemic Application Of Low Molecular Weight Heparin To Prevent Portal Vein Thrombosis After Splenectomy And Esophagogastric Devascularization

Objective To investigate the effect，which of the early systemicapplication of low-molecular-weight heparin in preventing veinthrombosis after splenectomy and esophagogastric devascularization.Methods The clinical data of50patients with portal hypertensionreceiving splenectomy and esophagogastric devascularization inChina-Japan Union Hospital of Jilin University from2008to2012wereanalyzed retrospectively. Those were divided into two groups for whethersystemic treated with low molecular weight heparin as the prevention ofthe thrombosis after the operation, the control group(24cases), theheparin group(26cases).To observe the changes of liver function and theformation of portal vein thrombosis in the period of2weeks to2monthsafter the operation. Contrast gender, age, preoperative and postoperativechanges in liver function and portal vein thrombosis, and the results wereanalyzed statistically.Results Between the control group and the heparin group, there is nosignificant difference in gender, age, and liver function before and aftersurgery (P>0.05). The incidence of portal vein thrombosis in controlgroup is62.5%, which is higher than the incidence in heparin group(34.62%). There is significant difference in incidence of portal veinthrombosis between the control group and the heparin group(0.01<P<0.05). Heparin group has no bleeding and other complicationsrelated to the use of low molecular weight heparins. Conclusions The early systemic application of low-molecular-weight heparin is effective in preventing vein thrombosis aftersplenectomy and esophagogastric devascularization, and does notincrease the morbidity risk.